RBTT-01. A PHASE 2 TRIAL WITH ABI-009 (NAB-SIROLIMUS) AS SINGLE-AGENT AND COMBINATIONS IN RECURRENT HIGH-GRADE GLIOMA (rHGG) AND IN NEWLY DIAGNOSED GLIOBLASTOMA (ndGBM)

BACKGROUND: The mTOR pathway is frequently activated in patients with GBM and is associated with reduced survival, making this pathway a promising target. However, mTOR inhibitors, including everolimus and temsirolimus, have poor brain penetration, limiting their potential use for GBM. ABI-009 is a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Kesari, Santosh, Juarez, Tiffany, Carrillo, Jose, Truong, Judy, Nguyen, Minhdan, Heng, Annie, Gill, Jaya, Nguyen, Hanh, Nomura, Natsuko, Grigorian, Berta, Hou, Shihe, Schmid, Anita, Desai, Neil
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Randomized Brain Tumor Trials in Development
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847626/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.913
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky